US EditionThe US will buy 2 million doses of an HIV prevention drug for low-income countries
The U.S. will provide 2 million doses of lenacapavir, a twice-yearly HIV prevention drug, to low-income countries by 2028 under the PEPFAR program to reduce new infections.
- On Thursday, the U.S. State Department said the government will buy lenacapavir doses under PEPFAR to cover up to 2 million people in low-income countries by 2028 and work with governments on distribution.
- After foreign aid cuts earlier this year, advocates asked about disruptions as the Trump administration slashed aid, causing health clinic closures and protesters near the White House on Sept. 2, 2025, highlighted withheld PEPFAR funds.
- Clinical trials last year showed lenacapavir offered near-complete protection, with over 99% of people at high risk of HIV remaining negative and each injection lasting six months.
- Gilead Sciences will provide lenacapavir at no profit and has signed agreements with generic drug manufacturers, while the U.S. will buy and supply doses to local governments as a stopgap until generics arrive.
- PEPFAR's long-term investment—more than $120 billion—paired with UNAIDS warnings highlights risks of more than six million new infections and 4.2 million AIDS-related deaths if cut amid 1.3 million new infections annually worldwide.
39 Articles
39 Articles
Pharmalittle: We're reading about PEPFAR and a Gilead drug, the FDA's rejection letters, and much more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is uncertain at the moment, but we hope to catch up on our reading, putter about the Pharmalot grounds, and promenade with the official mascots. We also hope to have time for another listening party, where the rotation will likely include this, this, this, this, and this. An…
Associated Press News
The US will buy 2 million doses of an HIV prevention drug for low-income countries
The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028.
Washington – Despite massive cuts to aid programs, the US government intends to fund an international program for affordable access to a drug to prevent HIV. The State Department in Washington justified its decision to promote the distribution of the drug lenacapavir yesterday by arguing that this would...
Coverage Details
Bias Distribution
- 66% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
